ArticleMolecular genetics & genomic medicine2026
Implementing a Tiered Genetic Testing Strategy for Muscular Dystrophies in Morocco: From Targeted Assays to Exome Sequencing.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMuscular dystrophies (MDs) are a heterogeneous group of inherited neuromuscular disorders. In Morocco, where consanguinity is common, recurrent variants have been reported; however, the overall molecular landscape remains underexplored.
methodsWe analyzed 716 patients referred over 32 years for suspected limb-girdle muscular dystrophy (LGMD) or dystrophinopathy using a stepwise approach. Multiplex PCR (MPCR) for DMD deletions and targeted Sanger sequencing of the SGCG:c.525delT variant were performed as first-line tests. Unsolved patients underwent next-generation sequencing (NGS), either via a customized gene panel or whole-exome sequencing (WES).
resultsMultiplex PCR for DMD deletions and targeted Sanger sequencing of the SGCG:c.525delT variant resolved nearly half of cases, demonstrating the efficiency of these cost-effective first-line tests. Unsolved patients underwent next-generation sequencing (NGS), via a customized gene panel or whole-exome sequencing (WES), though resource limitations prevented full coverage. Among tested cases, SGCA, CAPN3, and FKRP were the most frequently mutated genes after DMD and SGCG, with several novel or recurrent variants suggesting population-specific alleles.
conclusionsThese results highlight the genetic heterogeneity of MDs in Morocco and the value of combining targeted and broad genomic approaches, while underscoring the need to extend NGS to fully characterize unresolved patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.